Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Operating Leases (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Operating Leases for 4 consecutive years, with $419000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 43.07% to $419000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $419000.0, a 43.07% decrease, with the full-year FY2025 number at $419000.0, down 43.07% from a year prior.
  • Operating Leases was $419000.0 for Q4 2025 at Spruce Biosciences, down from $500000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.3 million in Q4 2022 to a low of $419000.0 in Q4 2025.
  • A 4-year average of $909000.0 and a median of $974000.0 in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: rose 8.52% in 2023, then crashed 43.07% in 2025.
  • Spruce Biosciences' Operating Leases stood at $1.3 million in 2022, then dropped by 19.19% to $1.0 million in 2023, then fell by 27.77% to $736000.0 in 2024, then plummeted by 43.07% to $419000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Operating Leases are $419000.0 (Q4 2025), $500000.0 (Q3 2025), and $580000.0 (Q2 2025).